Concentrations of aqueous humor endothelin (ET)-1 are increased in patients with primary open-angle glaucoma (POAG) as well as in animal models of glaucoma. Glucocorticoids have also been associated with glaucoma, in that topical administration of glucocorticoids can increase intraocular pressure by increasing outflow resistance in the trabecular meshwork (TM) in some individuals. Recent research has shown that dexamethasone (Dex), a synthetic glucocorticoid, can increase the release of ET-1 from human nonpigmented ciliary epithelial (HNPE) cells, a source of aqueous ET-1. In the present study, the downstream interaction of ET-1 with Dex in target TM cells, an action that may alter outflow resistance, was investigated. METHODS. A normal primary human TM (NTM) cell line and a TM cell line derived from a glaucomatous eye (GTM) were used. The cells were treated with vehicle or Dex. The mRNA levels of prepro-ET-1, endothelin receptor A (ET A ), and endothelin receptor B (ET B ) were measured by quantitative RT-PCR (QPCR). The protein expression of ET A and ET B receptors were investigated by Western blot analysis using polyclonal anti-ET A and anti-ET B antibodies, respectively, on plasma membrane fractions. Intracellular Ca 2ϩ ([Ca 2ϩ ] i ) mobilization mediated by ET-1 was measured using the Fura-2 AM fluorescent probe technique as an index of ET receptor function. ET-1-stimulated nitric oxide (NO) release was measured using a Griess colorimetric NO synthase assay kit. RESULTS. Both NTM and GTM cultured cells expressed prepro-ET-1 mRNA less abundantly than did HNPE cells, and Dex treatment had no effect on the mRNA expression of the ET-1 gene. TM cells expressed mRNA of ET A receptors as detected by QPCR, whereas the ET B message was not clearly delineated. Western blot analysis showed that both ET A and ET B receptor proteins were present. The ET A receptor was linked to calcium mobilization as ET-1 produced an increase in intracellular calcium release, and this increase was blocked with a selective ET A receptor antagonist. Dex failed to induce any change in the expression of the ET A receptor in both NTM and GTM cells, and this was supported by the absence of a Dex effect on the ET-1-induced calcium response. However, Dex treatment diminished ET B receptor protein expression and produced a decrease in ET-1-stimulated release of NO, a response mediated by ET B receptors in TM cells. CONCLUSIONS. The Dex-induced increase in ET-1 released by HNPE cells coupled to the downstream Dex-induced specific suppression of ET B receptor protein expression and declines in ET-1-mediated increase in NO released by TM cells could increase contraction and decrease relaxation of the TM and contribute to the declines in conventional aqueous humor outflow and increases in intraocular pressure that occur with glucocorticoids. (Invest Ophthalmol Vis Sci. 2003;44: 5301-5308)
G laucoma is commonly associated with elevated intraocular pressure (IOP), as occurs in POAG and results primarily from pathologic changes in the aqueous humor outflow pathway. Endothelin (ET)-1, a potent vasoactive peptide, may contribute to the etiology of POAG, as aqueous ET-1 concentrations are increased in POAG 1 and in animal models of glaucoma. 2 Moreover, chronic administration of ET-1 can produce optic neuropathy [3] [4] [5] and ET-1 has been proposed as a contributor to glaucoma pathophysiology. 6 In the anterior segment, HNPE cells have been shown to be a source for aqueous ET-1, as they endogenously synthesize and release ET-1. 7, 8 Endothelin-1 has a variety of physiological and/or pathophysiological ocular functions depending on the receptor subtype present and the tissue involved. There are two major classes of endothelin receptors, ET A and ET B , that have been cloned and characterized in mammalian species. 9, 10 Most commonly, ET A mediates ET-1-induced increase in intracellular calcium [Ca 2ϩ ] i 11 and vasoconstriction, 12 whereas ET B mediates vasodilation, apparently through increases in the production of NO. 13 ET B receptors are also involved in the clearance of circulating ET-1. 14 -17 Although it has been reported that ET-1 elicits [Ca 2ϩ ] i transients, 18 the expression and regulation of ET receptors in the trabecular meshwork (TM) and the downstream signaling events relating to outflow regulation are incompletely understood.
Glucocorticoids, potent immunosuppressants and anti-inflammatory agents, are associated with primary open-angle glaucoma (POAG). It has been reported that patients with POAG have elevated levels of the endogenous glucocorticoid cortisol in the blood 19 -21 and aqueous humor. 19 Ocular administration of glucocorticoids produces elevated IOP in some subjects. 22, 23 It has been well established that glucocorticoids change the morphology and activity of TM, including altering cell size and cytoskeletal organization, 24, 25 increasing extracellular matrix production, 26, 27 decreasing extracellular metalloproteinase activity, 28 and enhancing expression of a glaucoma gene, MYOC. 29, 30 Overall, glucocorticoids increase extracellular matrix material deposition in the TM and subsequently increase outflow resistance and IOP. Recently, we have shown that glucocorticoids can increase the release of ET-1 from HNPE cells 31 and the HNPE cells may represent the cell source for ET-1 in the aqueous. A novel signaling pathway for glucocorticoids involving ET-1 may be implicated in the increase in outflow resistance by glucocorticoids. We therefore investigated whether the downstream actions of ET-1 on the target TM cells were affected by glucocorticoids.
MATERIAL AND METHODS

Cell Culture
A primary normal TM cell line (NTM) from a 79-year-old normal white male donor, and a TM cell line from a 79-year-old white male donor who had had POAG (GTM) were used. These cells were isolated and propagated as previously described. 24, 25, 27, 30 The cells were grown at 37°C and 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM; Invitrogen-Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum and penicillin/streptomycin/ glutamine (Invitrogen-Gibco) and 44 mM NaHCO 3 . For experimental protocols, TM cells were grown to confluence, either on 100-mm culture dishes, 6-well culture plates (35-mm diameter/well), or 24-well culture plates (15-mm diameter/well). The culture medium was then changed to 5% FBS-DMEM and treated for 72 hours with an equivalent volume of vehicle (ethanol) or the glucocorticoid agonist dexamethasone (Dex; dissolved in ethanol; Sigma-Aldrich, St. Louis, MO), at a final concentration of 100 nM. RU486 (1 M; Biomol Research Laboratories, Inc., Plymouth Meeting, PA), an antagonist of glucocorticoid receptors, was used in some experiments. HNPE cells and astrocytoma cells U373 MG were used as positive controls for ET-1 or ET-receptor expression.
RNA Isolation and Quantitative Polymerase Chain Reaction
Total cellular RNA isolation and quantitative PCR (QPCR) were performed as previously described. 31 QPCR primers for human ppET-1, ET A , ET B , S15, and myocilin (Sigma-Genosys, The Woodlands, TX) are shown in Table 1 . The constitutively expressed "housekeeping" gene S15, a small ribosomal subunit protein, served as an internal control. Myocilin gene expression was used as an index of a glucocorticoid response. Myocilin primer pairs and QPCR amplification were designed according to Shepard et al. 32 The authenticity of QPCR products was confirmed by DNA sequencing and a BLAST search of the sequence through National Center for Biotechnology Information (http://www.ncbi.nim.nih.gov; data not shown). Quantification of relative RNA concentrations was achieved by using the comparative C T method (as described in User Bulletin 2: http://docs.appliedbiosystems. com/pebiodocs/04303859.pdf; Applied Biosystems, Foster City, CA).
Plasma Membrane Isolation and Western Blot Analysis
The isolation of plasma membranes and Western blot analysis were performed as previously described. 31 Briefly, after Dex treatment, plasma membrane fractions were isolated from both NTM and GTM cells. Protein concentration was determined using bicinchoninic acid (BCA) reagent. Western blot analysis for ET A and ET B receptors was performed using polyclonal anti-ET A or anti-ET B antibodies, respectively, with secondary horseradish peroxidase-conjugated donkey anti-rabbit IgG and visualized using an enhanced chemiluminescence (ECL) system. Nonspecific bands in the immunoblots were identified by preincubating the anti-ET A or anti-ET B antibodies with their respective receptor peptides. Densitometric analysis of the bands was accomplished using image-analysis software (Scion; National Institutes of Health, Bethesda, MD).
Measurement of Intracellular Ca 2؉ Mobilization
Dynamic video imaging was used to measure intracellular Ca 2ϩ within single cells according to a previously described method. 33 Both NTM and GTM cells were grown on 25- Imaging Co., West Chester, PA), and fluorescence signal ratios were collected every 5 seconds at 340:380 nm excitation wavelengths. ET-1 (100 nM) was added to the buffer, and changes in fluorescence ratios were recorded. BQ610 (Peninsula Laboratory Inc., Belmont, CA), an antagonist of the ET A receptor, was used at concentration of 1 M to determine whether ET-1-induced-Ca 2ϩ mobilization is mediated through the ET A receptor. The antagonist was added 30 minutes before the addition of ET-1. To convert fluorescence ratios to calcium concentrations, maximum and minimum ratios of fluorescence were obtained by applying 1 M of the calcium ionophore 4-bromo-A23187 (Calbiochem, CA), and 5 mM EGTA, respectively. The intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) was then calculated by using the equation devised by Grynkiewicz et al. 34 
Determination of Nitrite Accumulation in Culture Medium
After treatment with Dex for 72 hours, confluent NTM cells grown on 24-well culture plates were shifted to serum-free (SF) DMEM with 250 L SF-DMEM in each well, supplied with 100 nM Dex and additional 100 nM ET-1. After this 24-hour incubation, culture media were collected and NO was measured as nitrite, the final oxidation breakdown product of nitric oxide (NO) released into the culture medium using Griess colorimetric NO synthase (NOS) assay kit (Calbiochem, San Diego, CA) according to the manufacturer's protocol. Nitrite concentration in the culture medium was calculated from a constructed nitrite standard curve. An ET B receptor antagonist (1 M BQ788; Peninsula Laboratory Inc.) was added 30 minutes before the addition of ET-1 to determine the role of ET B receptor on NO release induced by ET-1.
RESULTS mRNA Expression of Prepro-ET-1, ET A , and ET B Receptors in NTM and GTM Cells
QPCR revealed that both NTM and GTM cells express prepro-ET-1 message; however, the prepro-ET-1 mRNA level was apparently much lower in TM cells than that in HNPE cells (Fig.  1) . Dex (100 nM) produced a significant increase in mRNA levels of prepro-ET-1 in HNPE cells, whereas it had no effect on prepro-ET-1 mRNA levels in TM cells (Fig. 1) .
Both NTM and GTM cells expressed abundant mRNA of ET A receptors, and Dex (100 nM) had no effect on the mRNA expression of ET A receptors, although these cells responded to Dex (100 nM) by significantly increasing myocilin mRNA expression (Fig. 2) . ET B receptor message expression was not detected in either NTM or GTM cells under control, Dex (100 nM), or serum-free overnight conditions, whereas as expected, ET B receptor mRNA was present in positive control cells tested, including brain astrocytoma and HNPE cells (data not shown).
Effects of Dex on ET A and ET B Receptor Protein Expression in NTM and GTM Cells
Because there was mRNA expression of ET A receptors while ET B receptor mRNA was not detected, we next determined whether TM cells express ET A and ET B receptor proteins and whether their levels would be regulated by Dex. Western blot analysis revealed that both ET A and ET B receptor proteins were present in NTM and GTM cells. Anti-ET A antibody recognized an approximate 43-kDa band (Figs. 3A, 3D) , and ET A receptor peptide completely blocked the recognition of this band (Figs.  3B, 3E) . Therefore, this 43-kDa protein was the ET A receptor. Treatment with Dex for 72 hours did not alter protein levels of the ET A receptor (Figs. 3C, 3F) .
Anti-ET B antibody recognized three bands sized approximately 80, 65, and 38 kDa (Figs. 4A, 4D ). Competing ET B peptide completely blocked the recognition of only the lowest band, whereas the other bands remained (Figs. 4B, 4E ). Therefore, the high molecular weight bands appear to be nonspecific bands, and the protein recognized with a size of 38 kDa is the ET B receptor. Dex treatment for 72 hours significantly decreased the protein levels of ET B receptors in both NTM and GTM cells (Figs. 4C, 4F) . Treatment with RU486 (1 M), an antagonist of glucocorticoid receptors, did not block Dexinduced decrease of ET B receptor protein and, of particular interest, RU486 alone showed partial agonist activity, as it also decreased the level of ET B receptors (Figs. 4G, 4H ).
Effects of Dex on ET-1-Mediated [Ca 2؉ ] i Mobilization
To determine whether ET A receptor function was altered by Dex treatment, the effects of ET-1 on [Ca 2ϩ ] i were measured in both NTM and GTM cells under vehicle control and Dex treatment conditions. As expected, primary TM cells produced a significant increase in [Ca 2ϩ ] i in response to 100 nM ET-1, and this response showed a typical biphasic phenotype with a transient spike followed by a sustained plateau (Figs. 5A, 5D ). This plateau was maintained even after ET-1 was removed (data not shown). The initial increase in [Ca 2ϩ ] i peaked at Ca 2ϩ concentrations well over 1 M, whereas baseline levels were initially below 100 nM ( 
Effects of Dex on ET-1-Induced NO Release from NTM Cells
To determine whether the decrease in the level of ET B receptors by Dex causes a similar decrease in functional response in TM cells, the effect of Dex on ET-1-induced release of NO was measured. A Griess colorimetric assay was used to detect the nitrite (the final oxidation product of NO) in culture medium. ET-1 (100 nM) significantly elevated nitrite concentrations in medium compared with that observed in control cells without ET-1 treatment, and BQ788 1 M, an ET B receptor antagonist, completely blocked the elevation of nitrite by ET-1 (Fig. 6 ). This result indicates that ET-1-mediated NO release occurs through activation of ET B receptors in TM cells. Dex (100 nM) alone did not alter NO release compared with the vehicle control; however, Dex treatment significantly decreased the ET-1-mediated NO release compared with cells without Dex treatment. This was consistent with the finding that Dex decreased ET B receptor expression in TM cells (as reported earlier in this paper) and that ET-1 stimulated NO release by activating ET B receptors.
DISCUSSION
It was postulated that aqueous ET-1 could influence the downstream effects of Dex on TM because it is known that ET-1 could contract TM and that TM contraction increases outflow resistance, whereas TM relaxation increases outflow facility. 35, 36 However, it was not known whether TM cells express ET-1 or whether Dex treatment stimulates expression of ET-1. In this study, QPCR detected weak expression of prepro-ET-1 mRNA in both NTM and GTM cells. Dex treatment did not change prepro-ET-1 mRNA expression in these cells. Compared with TM cells, HNPE cells expressed approximately four times higher basal levels of prepro-ET-1 mRNA in control cells, and Dex treatment caused a further threefold increase of prepro-ET-1 message. After Dex (100 nM) treatment, HNPE cells expressed more than 10 times higher levels of prepro-ET-1 mRNA compared with TM cells. We propose that NPE cells are the source of aqueous humor ET-1 and that released ET-1 may have downstream actions in TM. The finding that Dex treatment also enhanced ET-1 expression and release suggests that ET-1 may mediate Dex effects on target tissues such as TM cells.
ET-1 has diverse biological activities through different receptor subtypes, ET A , and ET B receptors. 6, 37 Although ET-1 has significant actions on the regulation of IOP, 38 functional ET receptor expression in TM, a tissue regulating outflow resistance, is not certain. Previously, ET A receptor mRNA but not ET B receptor message in TM cells was identified by RT-PCR. 18 Presently, only ET A receptor mRNA was detected by QPCR, whereas the ET B receptor message was not clearly delineated. However, Western blot analysis showed that both ET A and ET B receptor proteins were present. The reason for this apparent difference between message and protein could be due to the finding that ET B mRNA has a short intracellular half-life as the 3Ј noncoding region contains an AUUUA motif implicated in selective destabilization of mRNA. 10 The finding that ET B re- Western blot analysis revealed that the ET A receptor protein had a molecular mass of 43 kDa, whereas the ET B receptor was at slightly less than 40 kDa. Previously, we found ET A and ET B receptors had similar molecular weights in HNPE cells. 31 There have been numerous reports of different molecular weights for ET A and ET B receptors that range between 30 to 70 kDa. 39 -43 The ET A gene has a single transcription start site, whereas the murine and bovine ET B gene has been reported to have alternative transcriptional initiation sites. 44, 45 An ET B splice variant from alternative RNA splicing was identified in various human tissues. 46 Moreover, a metalloproteinase cleavage site was identified in the ET B protein sequence. 47 Overall, the apparent differences in reported molecular weights could be attributed to the source of antibodies, species or tissue specificity, posttranslation modification, different proteolytic processing, or ultimately the result of inaccuracy inherent in the estimation of the molecular weight of membrane proteins by SDS-PAGE.
QPCR and Western blot analysis demonstrated that 100 nM Dex treatment for 3 days did not alter ET A receptor mRNA and protein levels. In contrast, Dex treatment decreased ET B receptor protein levels. There are several mechanisms that could account for the effect of glucocorticoids on the regulation and expression of ET B target gene. Activated glucocorticoid-receptor complex can either bind to the glucocorticoid response element in target genes to regulate the transcription of these genes, or perhaps interfering with other transcription factors, such as NF-B and AP-1, and thereby preventing the actions of these transcription factors. 48 Some other glucocorticoid responses may involve glucocorticoid receptor activation of a primary response gene whose gene product in turn secondarily activates other genes. 32 However, the precise mechanism of glucocorticoid regulation of ET B receptor expression remains unclear. There is also very little information available on the regulation of endothelin receptor gene expression. Therefore, further experiments are needed to delineate the pathways that may be involved in the regulation of ET B receptor expression by Dex in TM cells.
RU486 did not block Dex's effects on the ET B receptor protein. It also appears that RU486 may function as a partial agonist, in that it had its own effect on ET B receptor protein level. In fact, RU486, a classic antagonist for both progesterone and glucocorticoids receptors, interferes with steroid-mediated activation but often confers an agonist activity on steroid receptors. 49 -51 RU486 could also function as a partial agonist in TM cells and HNPE cells. 31, 32 This partial agonist activity may explain the inability of RU486 to block the Dex-mediated decrease in ET B receptors.
ET - ET-1 was applied at 100 nM. Data are expressed as mean Nanomolar Ϯ SEM.
* Statistical significance was determined by t-test at P Ͻ 0.001 between baseline and ET-1-induced peak level. ation. 52 The signaling pathway coupled to ET B receptors has been linked to NO production. ET-1 activates endothelial NOS (eNOS) and hence NO production through ET B receptors in vascular endothelial cells. 13 ET-3 increases retinal blood flow through activation of ET B receptors, which also is dependent on NO production. 53 ET-1 and -3 also enhance inducible NOS (iNOS) expression, and this is mediated by ET B receptors in glial cells. 54 TM cells have been shown to express different isoforms of NOS and produce NO. [55] [56] [57] In the present study, we determined that the ET B receptors were linked to NO production in NTM cells. We detected basal levels of NO production in NTM cell culture media and showed that 100 nM ET-1 markedly increased NO release. An ET B receptor antagonist BQ788 completely blocked this stimulation of NO by ET-1. These findings indicated that ET-1-induced NO release is mediated by ET B receptors. Dex treatment decreased the ET B receptor protein level and also reduced ET-1-induced NO release, further implicating ET B in ET-1-induced release of NO in TM cells. There are several reports that NO donors could relax TM and lower IOP. 58 -60 This decrease of ET B receptor level and subsequent decrease of ET-1-induced release of NO by Dex could reduce NO mediated relaxation of TM. Moreover, ET B receptors are known to mediate ET-1 clearance.
14 -17 The decrease of ET B receptors in TM cells by Dex could also potentiate ET-1-mediated contraction of TM through ET A receptors.
In conclusion, Dex-induced specific suppression of ET B receptor protein expression and reduction in the ET-1-mediated increase in NO levels in TM cells with the concomitant increase of ET-1 release from HNPE cells by Dex could increase contraction and decrease relaxation of TM and reduce the intratrabecular space. This may exacerbate the effects of Dex on the outflow pathway, leading to increased outflow resistance and, consequently, elevated IOP.
